You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 139 No. 1, January 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (23)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Gastrointestinal/ Upper Foregut
 •Surgical Oncology
 •Alert me on articles by topic

Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Peritoneal Carcinomatosis Arising From Gastric Cancer

O. Glehen, MD; V. Schreiber, MD; E. Cotte, MD; A. C. Sayag-Beaujard, MD; D. Osinsky, MD; G. Freyer, MD, PhD; Y. François, MD; J. Vignal, MD; F. N. Gilly, MD, PhD

Arch Surg. 2004;139:20-26.

Hypothesis  The most common cause of palliative resection and recurrence in gastric cancer is peritoneal seeding. This study evaluates the efficacy of intraperitoneal chemohyperthermia after cytoreductive surgery in patients with peritoneal carcinomatosis arising from gastric cancer.

Design  Prospective clinical trial.

Setting  Surgical department at a university academic hospital.

Patients  Forty-nine consecutive patients with peritoneal carcinomatosis treated between January 1, 1989, and February 29, 2000.

Interventions  All patients underwent intraperitoneal chemohyperthermia with mitomycin C (40-60 mg); 21 patients had previously undergone extensive cytoreductive surgery.

Main Outcome Measures  Clinicopathologic factors that affect overall survival rates.

Results  With median follow-up of 99 months, overall median survival was 10.3 months. Two factors were significant independent predictors of survival by multivariate analysis: preoperative ascites (P = .04) and completeness of cancer resection (CCR) by cytoreductive surgery (P<.001). Median survival was 21.3 months for patients with CCR-0 (macroscopic complete resection) or CCR-1 (diameter of residual nodules <5 mm) and 6.1 months for patients with CCR-2 (diameter of residual nodules >5 mm) (P<.001). Four patients survived longer than 5 years.

Conclusions  An aggressive management strategy combining intraperitoneal chemohyperthermia with cytoreductive surgery is effective for patients with peritoneal carcinomatosis arising from gastric cancer. In highly selected patients (good general status, resectable primary tumor, resectable peritoneal carcinomatosis), this therapy may result in long-term survival.


From the Departments of Surgery (Drs Glehen, Osinsky, François, Vignal, and Gilly), Intensive Care (Dr Sayag-Beaujard), and Oncology (Dr Freyer), Centre Hospitalier Lyon-Sud, Pierre Bénite; and the Oncologic Hyperthermia Laboratory-EA Ciblage thérapeutique en Oncologie, Université CB Lyon-1, Oullins (Drs Glehen, Schreiber, Cotte, and Gilly), France.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer
Yan et al.
Ann. Surg. Oncol. 2007;14:2702-2713.
ABSTRACT | FULL TEXT  

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis
Lim et al.
Ann. Surg. Oncol. 2007;14:2309-2318.
ABSTRACT | FULL TEXT  

Outcome of Patients with Known Metastatic Gastric Cancer Undergoing Resection with Therapeutic Intent
Gold et al.
Ann. Surg. Oncol. 2007;14:365-372.
ABSTRACT | FULL TEXT  

Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery in Patients with Very Advanced Gastric Cancer
Cheong et al.
Ann. Surg. Oncol. 2007;14:61-68.
ABSTRACT | FULL TEXT  

Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy
Tuttle et al.
Ann. Surg. Oncol. 2006;13:1627-1632.
ABSTRACT | FULL TEXT  

Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions
Stewart et al.
Ann. Surg. Oncol. 2005;12:765-777.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.